The estimated Net Worth of Amarpreet Sawhney is at least $8.91 Миллион dollars as of 6 June 2019. Amarpreet Sawhney owns over 124,468 units of Ocular Therapeutix Inc stock worth over $8,912,902 and over the last 10 years Amarpreet sold OCUL stock worth over $0.
Amarpreet has made over 12 trades of the Ocular Therapeutix Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Amarpreet bought 124,468 units of OCUL stock worth $363,447 on 6 June 2019.
The largest trade Amarpreet's ever made was exercising 189,393 units of Ocular Therapeutix Inc stock on 21 December 2017 worth over $496,210. On average, Amarpreet trades about 36,428 units every 98 days since 2014. As of 6 June 2019 Amarpreet still owns at least 1,056,031 units of Ocular Therapeutix Inc stock.
You can see the complete history of Amarpreet Sawhney stock trades at the bottom of the page.
Amarpreet's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer и Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: